Blair William & Co. IL Cuts Position in Hologic, Inc. (NASDAQ:HOLX)

Key Points

• Blair William & Co. IL has significantly reduced its stake in Hologic, Inc. by 49.2%, selling 69,468 shares in the first quarter.
• Hologic reported $1.08 earnings per share for the latest quarter, exceeding analysts' estimates of $1.05, along with a revenue increase of 1.2% year-over-year.
• Hologic's stock has a current market capitalization of $14.88 billion and a target price range from analysts averaging $77.83.

Blair William & Co. IL cut its position in Hologic, Inc. (NASDAQ:HOLX - Free Report) by 49.2% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 71,819 shares of the medical equipment provider's stock after selling 69,468 shares during the quarter. Blair William & Co. IL's holdings in Hologic were worth $4,436,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also recently bought and sold shares of the company. Allworth Financial LP raised its position in shares of Hologic by 46.0% in the first quarter. Allworth Financial LP now owns 686 shares of the medical equipment provider's stock worth $40,000 after buying an additional 216 shares in the last quarter. Bank Julius Baer & Co. Ltd Zurich purchased a new stake in shares of Hologic in the 1st quarter valued at about $42,000. Larson Financial Group LLC raised its holdings in shares of Hologic by 6,016.7% in the 1st quarter. Larson Financial Group LLC now owns 734 shares of the medical equipment provider's stock valued at $45,000 after acquiring an additional 722 shares in the last quarter. Raiffeisen Bank International AG bought a new position in shares of Hologic in the fourth quarter worth approximately $49,000. Finally, West Financial Advisors LLC purchased a new position in Hologic in the 1st quarter worth approximately $50,000. 94.73% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of analysts recently weighed in on the company. Morgan Stanley boosted their target price on Hologic from $65.00 to $69.00 and gave the stock an "equal weight" rating in a research report on Thursday, July 31st. UBS Group boosted their price objective on shares of Hologic from $65.00 to $70.00 and gave the stock a "neutral" rating in a report on Thursday, July 31st. Needham & Company LLC reaffirmed a "hold" rating on shares of Hologic in a report on Tuesday, May 27th. Wall Street Zen cut shares of Hologic from a "buy" rating to a "hold" rating in a research report on Monday, May 5th. Finally, Raymond James Financial restated an "outperform" rating and set a $71.00 price target (down from $90.00) on shares of Hologic in a research report on Friday, May 2nd. Ten investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $77.83.

Hologic Trading Up 0.2%

NASDAQ:HOLX traded up $0.13 during trading hours on Friday, hitting $68.06. The company had a trading volume of 1,889,601 shares, compared to its average volume of 2,836,697. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.55 and a quick ratio of 2.81. The stock has a 50-day moving average price of $64.97 and a 200 day moving average price of $62.76. The company has a market capitalization of $15.14 billion, a PE ratio of 28.24, a price-to-earnings-growth ratio of 2.43 and a beta of 0.49. Hologic, Inc. has a 52 week low of $51.90 and a 52 week high of $84.67.

Hologic (NASDAQ:HOLX - Get Free Report) last announced its quarterly earnings results on Wednesday, July 30th. The medical equipment provider reported $1.08 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.05 by $0.03. Hologic had a net margin of 13.79% and a return on equity of 19.69%. The company had revenue of $1.02 billion for the quarter, compared to analysts' expectations of $1.01 billion. During the same quarter in the previous year, the company earned $1.06 earnings per share. Hologic's quarterly revenue was up 1.2% on a year-over-year basis. On average, equities research analysts predict that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.